Treatment Clinical Trials for Small Cell Lung Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for small cell lung cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 79

  • Nivolumab and Vorolanib in Treating Participants with Non-Small Cell Lung Cancer and Refractory Thoracic Tumors

    This phase I / II trial studies the side effects and best does of vorolanib when given in combination with nivolumab in treating participants with non-small cell lung cancer and thoracic tumors that aren't responding to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vorolanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and vorolanib may work better in treating participants with non-small cell lung cancer and thoracic tumors.
    Location: 5 locations

  • M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

    Background: Small cell lung cancer (SCLC) is an aggressive cancer. People with SCLC tend to be respond well to chemotherapy at first, but become resistant to treatment after a few months. Researchers want to see if combining two chemotherapy drugs with the drug M7824 will help the immune system fight tumors in people with SCLC. The chemotherapy drugs are topotecan and temolozomide. Objective: To determine the efficacy of M7824 plus topotecan or temozolomide in relapsed SCLC. Eligibility: Adults ages 18 and older diagnosed with SCLC whose disease has not responded to prior treatment Design: Participants will be screened with - Blood and urine tests - Medical history - Physical exam - Electrocardiogram to test heart function - Computed tomography and positron emission tomography scans Participants will be divided into three groups. Group A and Group B will get M7824 through a tube inserted in a vein for about 1 hour on Day 1 of a 21-day cycle. Group B will also get topotecan in a vein for about 30 minutes on Days 1 through 5 Group C will get M7824 for 1 hour on Days 1 and 15 of a 28-day cycle. They will also take temozolomide by mouth for 5 days each cycle. Group A will continue cycles as long as the disease responds to treatment. If it gets worse, they may be moved to Group B or C. During the study, participants will have physical exams and blood tests. They may have tumor samples taken. Participants will have a follow-up visit about 4 weeks after stopping the study drugs. They will have a physical exam and blood will be drawn.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

    The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline

    This phase I / II trial studies the best dose and side effects of stereotactic radiosurgery intreating participants whose cancer cells have spread to the brain from other organs in the body and studying their neurocognitive decline. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Stereotactic Radiosurgery followed by Tumor Treating Fields Therapy in Treating Participants with Small Cell Lung Cancer with Brain Metastases

    This trial studies how well stereotactic radiotherapy followed by tumor treating fields therapy work in treating participants with small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Given stereotactic radiosurgery and tumor treating fields therapy may help to reduce the chances of cancers coming back in other parts of your brain that are not being treated with stereotactic radiosurgery.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • Ipilimumab, Nivolumab, and Ad.p53-DC in Treating Participants with Relapsed Small Cell Lung Cancer

    This phase II trial studies the side effects of ipilimumab, nivolumab, and Ad.p53-DC, and to see how well they work in treating participants with small cell lung cancer that has come back after previous treatment. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Cancer vaccines, such as Ad.p53-DC, may help the body build an effective immune response to kill cancer cells by telling cells which targets to attack. Giving ipilimumab and nivolumab in combination with Ad.p53-DC, may kill more tumor cells in participants with relapsed small cell lung cancer.
    Location: Moffitt Cancer Center, Tampa, Florida

  • A Study of PLX2853 in Advanced Malignancies.

    The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Guadecitabine, Durvalumab, and Tremelimumab in Treating Patients with Extensive-Stage Small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of guadecitabine and to see how well it works with durvalumab and tremelimumab in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as guadecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Giving guadecitabine together with durvalumab and tremelimumab may work better in treating patients with extensive-stage small cell lung cancer.
    Location: 2 locations

  • Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

    Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect. It was discovered that only people with certain genes got this side effect. Researchers want to test mithramycin in people who do not have those certain genes. Objectives: To find the highest safe dose of mithramycin that can be given to people with chest cancer who have certain genes over 24 hours instead of spread out over a longer period of time. To see if mithramycin given as a 24-hour infusion shrinks tumors. Eligibility: People ages 18 and older who have chest cancer that is not shrinking with known therapies, and whose genes will limit the chance of liver damage from mithramycin Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Lung and heart function tests X-rays or scans of their tumor Liver ultrasound Tumor biopsy Participants will be admitted to the hospital overnight. A small plastic tube (catheter) will be inserted in the arm or chest. They will get mithramycin through the catheter over about 24 hours. If they do not have bad side effects or their cancer does not worsen, they can repeat the treatment every 14 days. Participants will have multiple visits for each treatment cycle. These include repeats of certain screening tests. After stopping treatment, participants will have weekly visits until they recover from any side effects.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed / Refractory Small Cell Lung Cancer

    Background: CRLX101 consists of a sugar molecule cyclodextrin linked to a chemotherapy drug called camptothecin. The combined molecule or nanoparticle drug conjugate travels through the blood. Once inside cancer cells, the chemotherapy drug is released from the molecule. Olaparib is a drug that may stop cancer cells from repairing the DNA damage caused by chemotherapy. Researchers want to see how safe it is to give CRLX101 and olaparib together and to see how well the combination treats a specific type of lung cancer called small cell lung cancer (SCLC). Objectives: To test the safety and maximum dose of CLRX101 and olaparib together. To test how well they treat small cell lung cancer. Eligibility: Adults 18 and older with small cell lung cancer. Design: Participants will be screened with standard cancer care tests. Participants will get the 2 study drugs in 28-day cycles. CRLX101 will be given every 2 weeks, through a small plastic tube in an arm vein. Olaparib will be taken by mouth twice a day most days. Participants will keep a pill diary. For Cycle 1, participants will have 3 visits. All other cycles will have 2 visits. At study visits, participants may have: Blood and hair samples taken History and Physical exam Questions about health and side effects Pregnancy test Optional tumor biopsy where a piece of tumor is removed by needle after numbing the skin. . CT scan Injection of CRLX101 (twice per cycle) Olaparib prescription Participants will have a follow-up visit 4 weeks after finish taking the drugs. They will have a physical exam and blood tests. They may have a tumor biopsy. The study team will call the patient every 3 months for follow up after completing the study treatment. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Patients with Relapsed or Progressive Small Cell Lung Cancer after First-Line Therapy

    This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride work in treating patients with small cell lung cancer that has come back or is growing, spreading, or getting worse after first-line therapy. Drugs used in chemotherapy, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Tremelimumab and Durvalumab with or without Radiation Therapy in Treating Patients with Relapsed Small Cell Lung Cancer

    This randomized phase II trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tremelimumab and durvalumab together with radiation therapy may kill more tumor cells.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • LCL161 Plus Topotecan for Patients With Relapsed / Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

    This trial will investigate the combination of two anti-cancer agents to treat patients with relapsed / refractory small cell lung cancer (SCLC) and ovarian cancers. Oral topotecan has US FDA approval for treating select gynecological cancers and SCLC. LCL161 is an investigational product that has been shown in clinical trials to work together with other anti-cancer agents. In this trial, investigators will determine the optimal dose of LCL161 and topotecan to administer to patients with relapsed / refractory SCLC and ovarian cancers, and examine the safety profile of the drug combination.
    Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

  • RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

    This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.
    Location: 2 locations

  • Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers Amd Extrapulmonary Small Cell Cancers

    Background: Chemotherapy damages cancer cell DNA so the cells die and the tumor shrinks. But it may stop working in some people over time. This is partly due to efficient DNA damage repair mechanisms used by tumor cells. VX-970 may stop cancer cells from preventing the repair of DNA damaged by chemotherapy. The purpose of this study is to see if using the chemotherapy drug topotecan along with the drug VX-970 will improve the response to chemotherapy. Objective: To study the safety and efficacy of VX-970 and topotecan in treating small cell lung cancer. Eligibility: Adults at least 18 years old with small cell lung cancer . Design: Participants will be screened with medical history, physical exam, blood and heart tests, and scans. Most of these tests are part of their routine care. Most of these tests will be repeated throughout the study. The study is set in 21-day cycles. Participants will get topotecan IV on days 1 through 5. They will get VX-970 IV on day 5 alone or on day 5 and day 2. Participants doctors will monitor them weekly for the first cycle, every 3 weeks after that. For Part 1 of this Study the doses of topotecan and VX-970 will be increased (according to the Protocol) to determine the maximum safe dose of the combination. The maximum safe dose of the combination is the dose at which no more than 1 in 6 people have an intolerable side effect. More participants will join in Phase 2. They will take the drugs at the maximum safe dose, on the same schedule as the drugs were taken in Phase 1. Participants will give samples of blood, hair, and tumor tissue (optional) at different times. They will discuss side effects at every visit. A month after stopping taking the drugs, participants will have a physical exam and blood drawn. They will have follow-up phone calls every 3 months.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Phase I / II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and / or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

    Background: - MEDI4736 is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two components. In the phase 1 component of the study, researchers want to investigate how well participants tolerate the combination of these drugs in treating advanced solid tumors, and in the phase 2 part of this study, researchers want to study if the combination treatments are effective in ovarian cancer. Objectives: - Phase 1 part of the study: To determine the safety of the combination of MEDI4736 with the drugs olaparib or cediranib. - Phase 2 part of the study: To determine how effective this combination is in treating ovarian cancer. Eligibility: - Phase 1 part of the study: Adults age 18 or older with advanced or recurrent solid tumors that have no standard treatment. - Phase 2 part of the study: Adults age 18 or older with advanced or recurrent ovarian cancer that has no standard treatment. Design: - Participants will be screened with medical history, physical exam, and blood and urine tests. They will have CT or MRI scans. For these, they will lie in a machine that takes pictures of their bodies. - Phase 2 part of the study requests the participants to have tumor samples removed. - Participants will get MEDI4636 through an IV. A small plastic tube will be inserted into a vein. The drug will be given every 2 weeks for 12 months. - Participants will take olaparib or cediranib by mouth every day. - Every 28 days will be 1 cycle. For cycle 1, participants will have 2 study visits. All other cycles, they will have 1 visit. At these visits, they will repeat the screening procedures. - Patients will keep a drug and diarrhea diary. - Patients on cediranib will monitor their blood pressure and keep a blood pressure diary. - Participants who can become pregnant, or have a partner who can become pregnant, must practice an effective form of birth control. - After 12 cycles, participants will have 1-3 months of follow-up.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients with Small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more cancer cells. Giving pembrolizumab with chemoradiotherapy or radiation therapy may be a better treatment for small cell lung cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to topotecan in subjects with metastatic small cell lung cancer.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

    The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. **The Phase 1b portion of the study is now complete**. Phase 2 portion of the study. The safest, maximally tolerated dose established as established in Phase 1 for Phase 2 is as follows -- Carfilzomib will be provided at 20 / 36 mg / m2 with Irinotecan dosed at 125 mg / m2. The purpose of the Phase 2 portion of the study is to assess 6 month survival of relapsed small cell lung cancer ins subjects treated with this combination therapy.
    Location: See Clinical Trials.gov

  • A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors

    This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and / or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
    Location: 3 locations

  • A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer

    The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1 / PD-L1 bispecific antibody, in participants with advanced solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

    The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
    Location: 2 locations

  • Niraparib and Temozolomide in Treating Patients with Extensive-Stage Small Cell Lung Cancer with a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

    This phase Ib / II trial studies how well niraparib and temozolomide work in treating patients with extensive-stage small cell lung cancer with a complete or partial response to platinum-based first-line chemotherapy. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving niraparib and temozolomide may work better in treating patients with extensive-stage small cell lung cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Guadecitabine and Carboplatin in Treating Patients with Extensive Stage Small Cell Lung Cancer

    This phase II trial studies how well guadecitabine and carboplatin work in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage). Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving guadecitabine and carboplatin may work better in treating patients with extensive stage small cell lung cancer compared to other standard of care chemotherapy drugs.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients with Locally Advanced Lung Cancer

    This pilot trial studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy and how well it works in treating patients with lung cancer that has spread to nearby tissues or lymph nodes. Photodynamic therapy consists of injecting a light sensitive drug called a photosensitizer, such as porfimer sodium, into the vein, waiting for it to accumulate in the tumor, and then activating it with a red laser light. Giving photodynamic therapy with porfimer sodium may reduce the tumor size in patients with lung cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York